SCRI Development Innovations, LLC: Small Cell Lung Carcinoma trials

The registry lists 10 Small Cell Lung Carcinoma studies with SCRI Development Innovations, LLC as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT01076504Phase 2Results posted
• Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerCompletedNCT00695292Phase 2Results posted
• Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00305942Phase 2Results posted
• Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerCompletedNCT00193375Phase 2Results posted
• LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedNCT02649673Phase 1
• Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerCompletedNCT00308529Phase 2
• Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00294931Phase 2
• Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerCompletedNCT00294190Phase 2
• Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerCompletedNCT00193401Phase 2
• Weekly Topotecan in the Second-Line Treatment of Small Cell Lung CancerCompletedNCT00193388Phase 2